中国抗体－Ｂ(03681.HK) 公布，向26名独立第三方发行合共1.12亿股新股，相当于扩大后股本9.37%；每股作价1.1元，较上交易日(13日)收报折让11.29%。集资净额1.24亿元，拟用于SM17的研发及临床项目以及潜在国际合作；目前不在产品线内的新候选药物的临床前研究、临床试验等准备工作；及一般营运资金。(de/d)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.